The ability of the Geneva homologous recombination deficiency (HRD) test to predict progression-free survival (PFS) in patients with high-grade ovarian cancer treated with poly (ADP-ribose) polymerase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback